Palvella Therapeutics (PVLA) announced the appointment of David Osborne, Ph.D. as Chief Innovation Officer, effective immediately. Dr. Osborne brings over 25 years of experience advancing innovative therapies from concept to FDA approval. He has contributed to the development of three dozen topical therapies, including ZORYVE cream and foam.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- Palvella Therapeutics price target raised to $66 from $52 at Canaccord
- Palvella Therapeutics price target raised to $75 from $38 at H.C. Wainwright
- Palvella Therapeutics Advances Rare Disease Pipeline
- Palvella Therapeutics price target raised to $60 from $50 at Chardan
- Palvella Therapeutics: Strong Financial Position and Clinical Progress Justify Buy Rating with Raised Price Target